BioPharma Dive April 22, 2022
Jonathan Gardner

Despite some hesitance, panelists backed the agency’s interest in demanding randomized trials for PI3K-blocking drugs.

The Food and Drug Administration appears ready to raise its approval standards for a well-known class of cancer drugs due to concerns they aren’t helping patients live longer, and may be harming them as well.

A panel of FDA outside advisers on Thursday voted 16-0, with one abstention, to recommend randomized, placebo-controlled trials for the drugs, known as PI3 kinase inhibitors, before they’re approved for broader use in blood cancers such as leukemia and lymphoma. The FDA isn’t bound to follow the advice of its advisory committees, but usually does so.

Since 2014, the FDA has granted multiple accelerated approvals to PI3K blockers, among them...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
FDA approves Akebia anemia pill, two years after rejection
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression

Share This Article